Tiziana Life Sciences Ltd (NASDAQ:TLSA) will present at BIO-Europe 2025, held Nov. 3–5 in Vienna.
Led by CEO Ivor Elrifi, the team will highlight its intranasal foralumab, the only fully human anti-CD3 antibody in clinical development, targeting neuroinflammatory and neurodegenerative diseases including na-SPMS, MSA, and early Alzheimer’s.